Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9226558 | 0.87 | ALDH1A1 (0.48) | KDM4ECYP3A4MAPTLTA4HALDH1A1 | |
| SCHEMBL26761783 | 0.83 | MAPK14 (0.51) | KDM4ECYP3A4MAPTALDH1A1HTT | |
| SCHEMBL8497858 | 0.83 | KDM4E (0.67) | KDM4ELTA4HALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL1351804 | 0.82 | KDM4E (0.62) | KDM4ECYP3A4MAPTALDH1A1HTT | |
| SCHEMBL24733025 | 0.82 | ST14 (0.61) | KDM4ECYP3A4MAPTALDH1A1HTT | |
| SCHEMBL12635837 | 0.82 | LTA4H (0.54) | KDM4ECYP3A4MAPTLTA4HALDH1A1 | |
| SCHEMBL7756966 | 0.81 | KDM4E (0.70) | KDM4ELTA4HALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL13973066 | 0.80 | KDM4E (0.59) | KDM4ELTA4HALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL1108563 | 0.80 | TAAR1 (0.67) | LTA4HEPHX2FFAR1 | |
| SCHEMBL9906839 | 0.80 | SRD5A2 (0.70) | LTA4HSRD5A2TSHRMAOAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745386-B2 | Coumarin based HSP90 inhibitors with urea and ether substituents | UNIVERSITY OF KANSAS (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190023698-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIVERSITY OF KANSAS (US) | 2019-01-24 | — | — | US | disclosed |
| US-10030006-B2 | Coumarin based Hsp90 inhibitors with urea and ether substituents | UNIVERSITY OF KANSAS (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2590656-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20160289217-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIVERSITY OF KANSAS (US) | 2016-10-06 | — | — | US | disclosed |
| US-9301951-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8916569-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| EP-2170848-B1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2014-10-22 | — | — | EP | disclosed |
| EP-0931788-B1 | Metalloprotease inhibitors | PFIZER LTD (GB) | 2002-11-06 | — | — | EP | disclosed |
| US-6090852-A | MATRIX METALLOPROTEASE INHIBITOR | PFIZER INC (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0931788-A2 | Metalloprotease inhibitors | Pfizer Limited (GB) | 1999-07-28 | — | — | EP | disclosed |
| EP-0677039-B1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LAB (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5783593-A | FUNGICIDE; ANTICHOLESTEROL AGENT | ABBOTT LABORATORIES (US) | 1998-07-21 | — | — | US | disclosed |
| US-5631401-A | Inhibitors of protein farnesyltransferase and squalene synthase | ABBOTT LABORATORIES (US) | 1997-05-20 | — | — | US | disclosed |
| WO-1996034850-A1 | CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-11-07 | — | — | WO | disclosed |
| EP-0677039-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | Abbott Laboratories (US) | 1995-10-18 | — | — | EP | disclosed |
| WO-1995021815-A1 | CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND SQUALENE SYNTHASE | ABBOTT LABORATORIES (US) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995012572-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1995-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745386-B2 | Coumarin based HSP90 inhibitors with urea and ether substituents | HSP90B1, HSP90AA1, HSP90AB1 | KDM4E 1906/4885CYP3A4 1053/4885MAPT 1230/4885 |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | KDM4E 3721/4885CYP3A4 582/4885MAPT 3957/4885 |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | KDM4E 3721/4885CYP3A4 582/4885MAPT 3957/4885 |
| US-10030006-B2 | Coumarin based Hsp90 inhibitors with urea and ether substituents | HSP90B1, HSP90AA1, HSP90AB1 | KDM4E 1792/4885CYP3A4 988/4885MAPT 1270/4885 |
| US-20160289217-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | HSP90B1, HSP90AA1, HSP90AB1 | KDM4E 1792/4885CYP3A4 988/4885MAPT 1270/4885 |
| US-20190023698-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | HSP90B1, HSP90AA1, HSP90AB1 | KDM4E 1792/4885CYP3A4 988/4885MAPT 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.